

1 **Non-severe vs severe symptomatic COVID-19: 104 cases from the outbreak on the cruise ship**
2 **“Diamond Princess” in Japan**

3
4 Sakiko Tabata, M.D.^{1†}, Kazuo Imai, M.D.^{1,2*†}, Shuichi Kawano, M.D.^{1,4}, Mayu Ikeda, M.D.¹,
5 Tatsuya Kodama, M.D.¹, Kazuyasu Miyoshi, M.D.¹, Hirofumi Obinata, M.D.^{1,3}, Satoshi Mimura,
6 M.D.¹, Tsutomu Kodera, M.D.¹, Manabu Kitagaki, M.D.¹, Michiya Sato, M.D.¹, Satoshi Suzuki,
7 M.D.¹, Toshimitsu Ito, M.D.¹, Yasuhide Uwabe, M.D.¹, Kaku Tamura, M.D.¹

8
9
10 1. Self-Defense Forces Central Hospital, 24-2-1, Ikejiri, Setagaya-ku, Tokyo, Japan

11 2. Department of Infectious Disease and Infection Control, Saitama medical university, 38 Moro,
12 Hongo, Iruma-gun, Saitama, Japan

13 3. Department of Emergency and Critical Care Medicine, Nippon Medical School, 1-1-5, Sendagi,
14 Bunkyo-ku, Tokyo, Japan

15 4. Japan Ground Self-Defense Force Medical Service School, 24-2-1, Ikejiri, Setagaya-ku, Tokyo,
16 Japan

17
18 * Corresponding author

19 †Both authors contributed equally

20
21
22
23
24
25
26
27
28
29
30
31 Corresponding author

32 Kazuo Imai, M.D.

33
34 Self-Defense Forces Central Hospital, 24-2-1, Ikejiri, Setagaya-ku, Tokyo, Japan

35 Department of Infectious Disease and Infection Control, Saitama medical university, 38 Moro,
36 Hongo, Iruma-gun, Saitama, Japan

37 Mail; k_imai@saitama-med.ac.jp

38 Tel; 03-3411-0151 or 049-276-111

39 **Abstract**

40

41 **Background**

42 The ongoing outbreak of 2019 novel coronavirus disease (COVID-19) is a global threat. Clarifying
43 its clinical features such as risk factors for disease progression is a pressing issue. We analyzed the
44 difference between non-severe and severe cases with COVID-19 as a result of the mass infection on
45 a cruise ship “Diamond Princess” in Japan.

46 **Methods**

47 In this retrospective, single-center study, total 104 cases of laboratory-confirmed COVID-19 were
48 enrolled from the mass infection on the cruise ship from 11th to 25th Feb, 2020, at Self-Defense
49 Forces Central Hospital in Japan. Clinical records, laboratory data, and radiological findings were
50 collected and analyzed. Clinical outcomes were followed up until 26th Feb, 2020.

51 **Findings**

52 Of the 104 patients, 47 were male. The median age was 68 years. During the observation period,
53 eight patients deteriorated into the severe cases. Finally, 76 and 28 patients were classified as
54 non-severe (asymptomatic, mild), and severe cases, respectively. Chest CT abnormalities were found
55 in 43 in non-severe cases and 23 in severe cases. The prevalence of consolidation on chest CT scan
56 and lymphopenia on the admission day was significantly higher in severe cases and in the eight cases
57 which worsened into severe disease during the observation period.

58 **Interpretation**

59 The high proportion of non-severe cases corrects the assessment of the trend of the outbreak.
60 Consolidation on chest CT scan and lymphopenia were possible risk factors for deterioration of
61 COVID-19 and contribute to the clinical management.

62

63 **Funding**

64 Not applicable.

65

66 **Research in context**

67

68 **Evidence before this study**

69 We looked into PubMed database for articles published in English up to 1st, Mar, 2020, using the
70 keywords “novel coronavirus”, “2019 novel coronavirus”, “2019-nCoV”, “Severe acute respiratory
71 syndrome coronavirus 2”, “SARS-CoV2”, “COVID-19”, “mass infection”, “herd infection”, “cruise
72 ship”, “Diamond Princess”, “asymptomatic” and “subclinical”. There were no published clinical
73 studies of featuring COVID-19 as a result of mass infection of cruise ship. We found a published
74 researches entitled “Characteristics of COVID-19 infection in Beijing.”, and “Radiological findings
75 from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study” comparing
76 patients with COVID-19 between asymptomatic, mild, and severe cases. However, above researches

77 did not describe the marker of deterioration, or the risk factors for disease progression.

78 **Added value of this study**

79 We presented a high proportion of asymptomatic and mild cases in patients infected with severe
80 acute respiratory syndrome coronavirus 2 (SARS-CoV2). On the admission day, the prevalence of
81 consolidation detected by CT scan and lymphopenia were significant higher in severe cases and in
82 cases which deteriorated into severe cases during the observation period. Consolidation on CT scan
83 and lymphopenia reflect the disease progression. This report contributes to the improvement of the
84 epidemiological and clinical management of COVID-19.

85 **Implications of all the available evidence**

86 There is a high prevalence of non-severe cases in patients infected with COVID-19 as a result of the
87 mass infection on a cruise ship. The prevalence of asymptomatic and mild cases of COVID-19
88 contributes to the further assessment on the trend of outbreak. Consolidation detected by CT scan
89 and lymphopenia are useful for the markers of disease progression.

90

91

92 **Introduction**

93

94 The 2019 novel coronavirus disease (COVID-19) is caused by a novel coronavirus – severe acute
95 respiratory syndrome coronavirus 2 (SARS-CoV2). The first case was reported in Wuhan, China, in
96 December 2019,¹ and the ongoing outbreak has been declared by the World Health Organization as a
97 Public Health Emergency of International Concern. Since the specific treatment for COVID-19 is
98 unknown, detection of the patients who are at high risk of severe illness is necessary in order to
99 prepare sufficient supportive therapy. Also, explosive increase in patients caused a collapse of health
100 care system. Therefore triage of the patients and transportation to the proper facilities are required.
101 The knowledge of the clinical characteristics of the disease and pathogenicity of the virus is
102 increasingly accumulated. However, detail of the clinical characteristics is still unknown and most of
103 the articles previously printed are mainly focused on the severe cases of COVID-19.²⁻⁵ In Japan, a
104 large number of infection among passengers and crew members of the cruise ship “Diamond
105 Princess” occurred in Feb, 2020. By 1st March, 2020, over 700 people were laboratory-confirmed
106 with SARS-CoV2 infection. All symptomatic and asymptomatic cases were referred to the medical
107 institutions designated for infectious diseases in accordance with Infectious Diseases Control Law of
108 Japan. Approximately 15% of the laboratory-confirmed cases were admitted to Self-Defense Forces
109 Central Hospital in Japan.

110 The prevalence of asymptomatic and mild cases of COVID-19 contributes to the assessment of
111 epidemic trend⁶. In the clinical settings, identifying the patients who are at risk of deterioration is
112 essential. For these reasons, understanding of the differences between non-severe (asymptomatic and
113 mild) cases and severe cases is required.

114 Therefore, we retrospectively collected and analyzed detailed clinical findings in hospitalized cases

115 with COVID-19 of the cruise ship outbreak, including asymptomatic/mild and severe symptomatic
116 cases, at the Self-Defense Forces Central Hospital in Japan.

117

118 **Methods**

119

120 **Study design and patients**

121 We conducted a retrospective review on the medical records of 104 laboratory-confirmed patients
122 with COVID-19 who were referred to the Self-Defense Forces Central Hospital in Japan, since 11th
123 to 25nd Feb 2020. In the cruise ship, all patients were examined under quantitative reverse
124 transcription polymerase chain reaction (qRT-PCR) or nested polymerase chain reaction (PCR) for
125 SARS-CoV2 in the pharyngeal swab or sputum according to the recommendation by the National
126 Institute of Infectious Disease at the public health institute.⁷ This study was reviewed and approved
127 by the Japan Self-Defense Forces Central Hospital (approval number 01-011). Both written and oral
128 informed consent was obtained from each enrolled patient.

129 **Data collection**

130 We retrospectively collected patient information from the electronic medical records of our hospital,
131 including clinical records, laboratory findings, and chest CT scans. All information were collected
132 and reviewed by two study investigators (ST and KI),

133 **Definitions**

134 The geographical regions were classified according to the standard country or area codes for
135 statistical use (M49) by the United Nations Statistics Division. Asymptomatic cases were defined as
136 patients with no history of clinical signs and symptoms. Severe symptomatic cases were defined as
137 patients showing clinical symptoms of pneumonia (dyspnea, tachypnea, saturation of percutaneous
138 oxygen (SpO₂) <93%, and patients' need for oxygen therapy).⁸ Other symptomatic cases were
139 classified as mild cases.

140 **Statistical analysis**

141 Continuous variables were expressed as mean standard deviation (SD) or median interquartile range
142 [IQR], and compared with under the T-test or Wilcoxon rank-sum test for parametric or
143 non-parametric data, respectively; categorical variables were expressed as number (%) and compared
144 by χ^2 test or Fisher's exact test. Multivariable logistic regression analysis was used for multivariate
145 analysis. The final multivariable logistic regression models were adjusted for age, sex, smoking, and
146 any underlying disease. A two-sided *p*-value of less than 0.05 was considered statistically significant.
147 All statistical analyses were calculated using Stata13.

148 **Role of the funding source**

149 There was no funding source for this study.

150

151 **Result**

152

153 During the observation period, total 107 laboratory-confirmed patients with COVID-19 from the
154 cruise ship were hospitalized at the Self-Defense Forces Central Hospital in Japan. Three patients
155 were excluded from this study because of their withdrawal to join this study. Therefore, the
156 remaining 104 patients were analyzed. Clinical history, physical examination and chest CT scan were
157 evaluated on the admission day, and blood tests were conducted within two days. The characteristics
158 of the 104 patients are presented in Table 1. The age range was 25–93 years (median, 68 years; IQR,
159 46.75–75), and 47 patients (45.2%) were male. The most common nationality of patients was Eastern
160 Asia, which included Japan and China. The observation period is from three to fifteen days (median,
161 10; IQR, 7–10 day). Fifty two patients (50.0 %) had comorbidities.

162 The clinical findings and severity of the patients before and after admission are shown on Table 2. Of
163 the 104 patients, the most common clinical signs and symptoms presented before the admission were
164 fever (28.8%) and cough (27.9%). On the admission day, 43 patients (41.3%) didn't show any
165 symptoms; therefore, these patients were classified as asymptomatic. Forty-one patients (39.4%)
166 were classified as mild cases, and 20 patients (19.2%) were severe cases. During the observation
167 period, 80 new clinical signs and symptoms arose. Seven asymptomatic cases were reclassified as
168 mild cases. Three asymptomatic cases and five mild cases required oxygen therapy because of the
169 pneumonia of COVID-19; thus, they were reclassified as severe cases. The confirmed classification
170 of severity at the end of the observation is; 33 patients (31.7%) as asymptomatic, 43 patients (41.3%)
171 as mild, and 28 patients (26.9 %) as severe. Describing about the eight patients who deteriorated and
172 reclassified as severe cases, the age range was 42–87 years (median, 70 years; IQR, 70–77), and five
173 patients (62.5%) were male. The period of deterioration from onset was 1- 5 days (median, 4 days;
174 IQR, 2.5-5). Also, of all the patients, 14 patients (13.5%) needed oxygen therapy, and a patient
175 required mechanical ventilation. None of the patients died during the observation period.

176
177 The differences in clinical, laboratory, and radiographic abnormality on the admission day between
178 non-severe cases and severe cases were analyzed. There were no significant differences observed in
179 the distribution of age, sex, and comorbid condition between two groups (Table 3). Of the 76
180 non-severe patients, 43 patients (56.6%) manifested the abnormal findings on CT scan with various
181 patterns. (Figure 1). In univariate analyses, the prevalence of CT abnormality detected on the
182 admission day was significantly higher in the severe cases than in non-severe cases (85.2% vs
183 56.6%; $p = 0.03$; OR, 3.53; 95% CI; 1.21-10.27). Significant differences in the prevalence of the CT
184 pattern were found between severe and non-severe cases as follows: bilateral lung findings (57.1%
185 vs 28.9%; OR, 3.27; 95% CI; 1.33–8.06; $p = 0.01$), multifocal ground-glass opacity (GGO) (63.0%
186 vs 34.2%; OR, 2.97; 95% CI; 1.21–7.26; $p = 0.02$), and consolidation (48.1% vs 19.7%; OR, 3.52;
187 95% CI; 1.38–8.96; $p = 0.01$). With regard to blood tests, the elevation of aspartate transaminase
188 (AST) ≥ 38 IU/dL (32.1% vs 11.8%; OR, 3.52; 95% CI; 1.22-10.12; $p = 0.01$) and depletion of
189 lymphocyte count $<1,200$ (/ μ L) (lymphopenia) (57.1% vs 25.0%; OR, 4.00; 95% CI; 1.61-9.95; $p <$
190 0.01) in severe cases was significantly higher than in non-severe cases. Subsequently, the patients

191 who worsened to severe cases during the observation period (n=8) were compared with the patients
192 in non-severe cases (n=76). In the patients who deteriorated, eight patients (100.0%) presented the
193 radiographical abnormality on CT in prior to the typical pneumonia symptoms (Figure 2).
194 Consolidation on chest CT scan and lymphopenia were found in six (75.0%) and five patients
195 (62.5%), respectively. In univariate analyses, the prevalence of consolidation (75.0% vs 19.7%; OR,
196 12.20; 95% CI; 2.23–66.59; $p = 0.04$) and lymphopenia (62.5% vs 25.0%; OR, 5.00; 95% CI;
197 1.10–22.92; $p = 0.04$) were found to be significant higher in the patients who worsened to severe
198 cases.
199 In multivariate analysis, the prevalence of consolidation detected by chest CT scan (adjusted OR:
200 3.24; 95% CI; 1.04-10.40; $p = 0.04$), and lymphopenia (adjusted OR, 4.30; 95% CI; 1.50-13.75; $p <$
201 0.01) were found to be significant higher in severe cases.

202

203

204 Discussion

205

206 In the outbreak of COVID-19 on the cruise ship “Diamond Princess,” members of the cruise ship
207 were tested by PCR for SARS-CoV2 and all laboratory-confirmed cases were referred to the
208 hospitals. This situation is worthy to note because we observed the clinical course of even
209 asymptomatic or mild symptomatic patients, which have not been investigated in the reports
210 previously published.²⁻⁵

211 The possible risk factors for deterioration of COVID-19 have been unclear, because patients do not
212 visit hospitals if they are asymptomatic or only mild symptomatic. Based on the previous findings of
213 COVID-19 in China, old age, male sex, and presence of comorbidities may be risk factors for disease
214 progression and poor prognosis.¹ In this study, the prevalence of consolidation detected by chest CT
215 scan and lymphopenia were significantly higher in severe cases and in the cases that worsened to
216 severe condition during the observation period than in non-severe cases ($p < 0.05$). Therefore,
217 consolidation and lymphopenia are considered as possible risk factors for disease progression of
218 COVID-19. Pan F, et al. and Shi H, et al. reported that the pattern of abnormal lung findings was
219 varied from GGO into consolidation during the time course of COVID-19⁹, and the appearance of
220 consolidation became more frequent in patients within 1-3 weeks after symptom onset.¹⁰ Previous
221 reports showed 55% of patients with COVID-19 developed dyspnea a median of 8 days (IQR,
222 5.0–13.0) after symptom onset,¹ thus, the timing of appearance of consolidation on CT scan is
223 associated with the timing of deterioration of the disease. Generally, consolidation is easily
224 detectable in chest X-ray. It may be useful for evaluation for risk of the disease progression in the
225 patients with COVID-19 in the setting with limited resources,
226 With regard to blood tests, lymphopenia is a common feature in symptomatic COVID-19^{11,12}, and
227 this can be caused by either direct effect of the SARS-CoV2 or cytokines. Lymphopenia was also
228 frequently found in SARS¹³, and was considered as a marker of disease activity.¹⁴ Our findings

229 suggest that lymphopenia may also reflect the disease progression and lead a new insight into the
230 phenotype and pathogenicity of SARS-CoV2.

231 CT scan showed a high prevalence of abnormality in lungs in non-severe cases (56.6 %) and severe
232 cases (85.1 %), and that findings are also seen even in asymptomatic cases. Shi H, et al. also
233 mentioned these asymptomatic abnormal lung findings in their report focusing on the radiological
234 findings on CT scan of COVID-19 cases.¹⁰ This interesting clinical feature of the SARS-CoV2
235 infection has not been reported in the SARS-CoV or Middle East respiratory syndrome coronavirus
236 (MERS-CoV). All of the eight patients, who reclassified as severe cases from non-severe case during
237 the observation period, presented CT abnormality in advance of the appearance of typical pneumonia
238 symptoms. Moreover, less than half of the patients had no obvious symptoms such as fever and
239 cough. These facts warn us that COVID-19 pneumonia progresses “silently” without any remarkable
240 symptoms. Assessment with the blood test and chest CT scan might lead to a successful devotion of
241 medical resources to the patients who have the risk of disease progression in the setting and mass
242 infection as well as in the normal clinical settings. On the other hand, majority of asymptomatic
243 cases with radiological abnormality on CT scan did not develop the severe pneumonia. The
244 difference of clinical outcomes may associate with their background, and genetic and pathogenic
245 diversity of SARS-CoV2. Understanding of its relevance to the duration of virus shedding or to the
246 incidence rate of secondary bacterial pneumonia is important for improvement of clinical
247 management. Further study is required to clarify this clinical impact in the asymptomatic and mild
248 patients with COVID-19.

249 It is important to determine the proportion of asymptomatic and mild cases to assess not only the risk
250 of subsequent outbreaks but also the future trends.⁶ Generally, asymptomatic and mild infections
251 contribute to herd immunity and its dampening effect on epidemic spread.^{6,15} However, the
252 prevalence of asymptomatic and mild cases of COVID-19 has not been elucidated because detection
253 of the asymptomatic case by RT-PCR is not realistic, except for the limited situation like a mass
254 infection. In this study, we showed that 73.0 % of the patients in the mass infection on a cruise ship
255 were asymptomatic and mild cases, and the proportion was higher than previously reported^{6,11,16}.
256 However, the sensitivity of RT-PCR is considered insufficient¹⁷, and the accurate prevalence is still
257 underestimated. The serological screening by using specific antibody of COVID-19 is expected to
258 confirm our result. Many countries and institutions are using contact tracing in the surveillance of
259 COVID-19. However, it is suggested that the large number of asymptomatic and mild patients may
260 have been overlooked in the past.

261 Viral RNA was frequently detected through throat swabs or sputum even in asymptomatic and mild
262 symptomatic patients. In Germany and China, the transmission from an asymptomatic patient to
263 another person has been reported.¹⁸⁻²⁰ Zou L, et al. showed that viral RNA was detected in the upper
264 respiratory specimen in asymptomatic patients over 11 days, and the viral load of an asymptomatic
265 patient was equivalent to that of symptomatic cases.²¹ Also, the fact that we found CT abnormality
266 even in the asymptomatic patients also suggest that they may have a certain amount of viral load.

267 Previous findings along with our results may support the evidence that asymptomatic patients also
268 shed the SARS-CoV2 from the upper respiratory tract. Also, during the mass infection on the cruise
269 ship, there was a possibility that both asymptomatic and symptomatic patients spread the
270 SARS-CoV2. Further study is desired to clarify the transmission from an asymptomatic patient to
271 another person.

272 The limitations of this study were the selection bias and small number of patients. We enrolled the
273 ideal homogeneous clusters of relatively healthy person who can get aboard a cruise ship for a long
274 term. However, our patient population and was not completely representative of patients in the
275 normal clinical settings. In addition, there were only a few patients who deteriorated into severe
276 cases from non-severe case during the observation period in this study. Therefore, further multicenter,
277 multi-national cohort study is desired to determine the prediction marker of diseases progression.

278

279

280 **Conclusion**

281

282 Our study highlighted the high prevalence of asymptomatic and mild cases of COVID-19 as a result
283 of mass infection on a cruise ship. Consolidation on CT scan and lymphopenia may reflect the risk of
284 disease progression. Our findings contribute to estimate the future trend of outbreaks, better
285 understanding of clinical course and improvement of the management of COVID-19. Further cohort
286 study is needed to determine the prediction marker of diseases activity.

287

288 **Competing interest**

289

290 The authors declare that they have no conflicts of interests.

291

292 **Funding**

293

294 This research did not receive any specific grant from funding agencies in the public, commercial, or
295 nonprofit sectors.

296

297 **Authors' contributions**

298

299 TI and KT, study conception and design; ST and KI, collecting data and performed the data analysis;
300 ST, KI, MI, and KM manuscript drafting, and editing; TaK, HO, SK, TsK, MK and SM, manuscript
301 revision; MS, SS and UY, study supervision. All authors read and approved the final manuscript.

302

303 **Acknowledgments**

304

305 We thank everyone involved in the COVID-19 management and treatment team from the
306 Self-Defense Forces Central Hospital in Japan and members who were assembled from other
307 institutes of Japan Self-Defense Forces. Particularly, we thank Dr. Koji Kameda, Dr. Takayuki
308 Yamamoto, Dr. Daishi Higashiyama, Dr. Yoshitaka Imoto, Dr. Masataka Miyama, Dr. Tsukasa
309 Mizuno, Dr. Kento Kato, Dr. Masaru Honda, Dr. Shoji Takeda, and Dr. Masumi Ogawa, Dr. Shingo
310 Tanaka, Dr. Hisashi Sasaki, Dr. Mitsuki Yamaga, Dr. Shinichiro Ota and Dr. Hiroaki Taniguchi for
311 supporting the data collection, and Dr. Akira Fujikawa and Dr. Shohei Inui for the interpretation of
312 chest CT scan. We also thank Mr. Shingo Tamaki (School of Tropical Medicine and Global Health,
313 Nagasaki University, Japan) for the supporting statistical analysis, and Colonel. Kazuhiro Nakaya
314 (Medical Department, Ground Staff Office, Ministry of Defense) for the scientific advice.

315

316

317 **References**

318

- 319 1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
320 coronavirus in Wuhan, China. *The Lancet* 2020; **395**: 497-506.
- 321 2. Zhang JJ, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected by
322 SARS-CoV-2 in Wuhan, China. *Allergy* 2020.
- 323 3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of
324 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *The Lancet* 2020; **395**:
325 507-13.
- 326 4. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019
327 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020.
- 328 5. Li K, Wu J, Wu F, et al. The Clinical and Chest CT Features Associated with Severe and
329 Critical COVID-19 Pneumonia. *Investigative Radiology* 2020.
- 330 6. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A Novel Coronavirus
331 Emerging in China - Key Questions for Impact Assessment. *The New England Journal of Medicine*
332 2020; **382**: 692-4.
- 333 7. Nao N, Shirato K, Katano H, et al. Detection of second case of 2019-nCoV infection in
334 Japan. National Institute of Infectious Diseases.
335 [.https://www.niid.go.jp/niid/images/vir3/nCoV/method-niid-20200123-2_erratum.pdf](https://www.niid.go.jp/niid/images/vir3/nCoV/method-niid-20200123-2_erratum.pdf) [Latest
336 accessed 1/Mar/2020]
- 337 8. Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. Therapeutic and triage strategies for
338 2019 novel coronavirus disease in fever clinics. *The Lancet Respiratory Medicine*.
- 339 9. Pan F, Ye T, Sun P, et al. Time Course of Lung Changes On Chest CT During Recovery
340 From 2019 Novel Coronavirus (COVID-19) Pneumonia. *Radiology* 2020: 200370.
- 341 10. Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19
342 pneumonia in Wuhan, China: a descriptive study. *The Lancet Infectious Diseases*.

- 343 11. Guan W-j, Ni Z-y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in
344 China. *New England Journal of Medicine* 2020.
- 345 12. Chen H, Guo J, Wang C, et al. Clinical characteristics and intrauterine vertical transmission
346 potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records.
347 *The Lancet*.
- 348 13. Wong RS, Wu A, To KF, et al. Haematological manifestations in patients with severe acute
349 respiratory syndrome: retrospective analysis. *BMJ* 2003; **326**: 1358-62.
- 350 14. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of
351 144 patients with SARS in the greater Toronto area. *JAMA* 2003; **289**: 2801-9.
- 352 15. Bellan SE, Pulliam JRC, Dushoff J, Meyers LA. Ebola control: effect of asymptomatic
353 infection and acquired immunity. *The Lancet* 2014; **384**: 1499-500.
- 354 16. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus
355 (2019-nCoV) in Wuhan, China. *Journal of Medical Virology* 2020; **92**: 441-7.
- 356 17. Huang P, Liu T, Huang L, et al. Use of Chest CT in Combination with Negative RT-PCR
357 Assay for the 2019 Novel Coronavirus but High Clinical Suspicion. *Radiology* 2020: 200330.
- 358 18. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV Infection from an
359 Asymptomatic Contact in Germany. *The New England Journal of Medicine* 2020.
- 360 19. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19.
361 *JAMA* 2020.
- 362 20. Yu P, Zhu J, Zhang Z, Han Y, Huang L. A familial cluster of infection associated with the
363 2019 novel coronavirus indicating potential person-to-person transmission during the incubation
364 period. *The Journal of Infectious Diseases* 2020.
- 365 21. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens
366 of Infected Patients. *The New England Journal of Medicine* 2020.

367
368

369 **Figure Legends**

370

371 Figure 1. The CT pattern of abnormal lung findings among asymptomatic patients with COVID-19.
372 A patient 73 years old, female. The patchy non-segmental ground glass opacity (GGO) adjacent to
373 the parietal pleura in the right upper lobe (A and B), and in both lower lobes (C and D). A patient 70
374 years old, female. The GGO with interlobular septal thickening (crazy-paving appearance) adjacent
375 to the parietal pleura in the both lower lobes (E). A patient 76 years old, male. CT scan showed the
376 GGO with consolidation, bronchial wall thickening, and bronchiectasis in the left lower lobe (F).

377

378 Figure 2. The progress of CT findings in a patient with COVID-19. A male patient 75 years old was
379 asymptomatic on the admission day. On the fourth day of admission, he showed tachypnea and
380 hypoxemia, and treated oxygen therapy. On the admission day, Chest CT scan showed multifocal

381 GGO adjacent to the parietal pleura in multiple lobes with emphysematous changes (A, B and C). On
382 the tenth day of admission, a follow-up chest CT scan showed an increase of extent of GGO with
383 crazy-paving appearance (D, E and F).

384

385 **Table1: The baseline characteristics of patients with COVID-19 from the cruise ship**

Total number of patients (n = 104)	
Characteristics	
Age	68 [46.75–75]
Sex (male)	47 (45.2 %)
Observation period (days)	10 [7-10]
The period onset to admission (days)	5 [2 - 7]
Nationality	
Eastern Asia	55 (52.9%)
Southeast Asia	21 (20.2%)
Europe	4 (3.8%)
Northern America	14 (13.5%)
Oceania	4 (3.8%)
Others	6 (5.8%)
Smoking	
Yes	18 (17.3%)
Comorbid condition	
Total	52 (50.0%)
Cardiovascular	31 (29.8%)
Endocrine	9 (8.7%)
Diabetes mellitus	7 (6.7%)
Respiratory	7 (6.7%)
Carcinoma	4 (3.8%)

386 Data are n (%) or median (IQR), unless otherwise specified.

387

388 **Table 2. Clinical findings and severity of patients with COVID-19**

	Number (%) n = 104	
	Started before the admission	End of the observation period
Signs and symptoms		
Fever	30 (28.8%)	36 (34.6%)
Cough	29 (27.9%)	43 (41.3%)
Malaise	12 (11.5%)	22 (21.2%)
Headache	10 (9.6%)	18 (17.3%)
Sore throat	11 (10.6%)	11 (10.6%)
Runny nose	16 (15.4%)	25 (24.0%)
Diarrhea	8 (7.7%)	10 (9.6%)
Dyspnea	7 (6.7%)	19 (18.3%)
Tachypnea	16 (15.4%)	24 (23.1%)
SpO ₂ < 93 %	3 (2.9%)	14 (13.5%)
Treatment		
Oxygen therapy	3 (2.9%)	14 (13.5%)
Mechanical ventilation	-	1 (1.0%)
Severity		
Asymptomatic	43 (41.3%)	33 (31.7%)
Mild	41 (39.4%)	43 (41.3%)
Severe	20 (19.2 %)	28 (26.9%)

389 Data are n (%)

390

391 **Table 3. The differences in clinical characteristics between non-severe cases and severe cases on**
 392 **the admission day**

	Non-severe n = 76	Severe n = 28	Univariate		Multivariate	
			p-value	OR	p-value	Adjusted OR
Characteristics						
Age	66.5 [44.75-74]	72.5 [55.25-76.5]	0.08		0.62	
Sex (male)	32 (42.1%)	15 (53.6%)	0.37		0.28	
Smoking						
Yes	11 (14.5%)	7 (25.0%)	0.24		0.08	
Underlying disease						
Total	34 (44.7%)	18 (64.3%)	0.12		0.18	
Radiographically findings on the day of admission						
Abnormal lung finding	43 (56.6%)	23 (82.1%)	0.02*	3.53 (1.21-10.27)		
Bilateral lung findings	22 (28.9%)	16 (57.1%)	0.01*	3.27 (1.33-8.03)		
Multifocal GGO	26 (34.2%)	17 (60.7 %)	0.02*	2.97 (1.21-7.26)		
Consolidation	15 (19.7%)	13 (46.4 %)	0.01*	3.52 (1.38-8.96)	0.04*	3.24 (1.04 - 10.40)
Laboratory findings on the day of admission						
AST > 38 (IU/L)	9 (11.8%)	9 (32.1%)	0.02*	3.52 (1.22-10.12)	0.07	
ALT > 45 (IU/L)	10 (13.2%)	7 (25.0%)	0.22			
LDH > 230 (IU/L)	17 (22.4%)	10 (35.7%)	0.21			
CRP > 1.0 (mg/dL)	34 (44.7 %)	19 (67.9%)	0.07			
White blood cell count < 4000 (/μL)	13 (17.1%)	6 (21.4%)	0.58			
Platelet count < 20 (×10 ⁴ /μL)	6 (7.9%)	2 (7.1%)	1.00			
Lymphocyte count <1200 (/μL)	19 (25.0%)	16 (57.1%)	< 0.01*	4.00 (1.61-9.95)	< 0.01*	4.30 (1.50-13.75)

393 Data are n (%), or median [IQR], unless otherwise specified.

394 OR, odds ratio; 95% CI, 95% confidence interval; GGO, ground-glass opacity; AST, aspartate
 395 aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CRP, C reactive
 396 protein.

397 Asterisk indicated the statistical significance.

398

399



